News headlines about ViewRay (NASDAQ:VRAY) have been trending somewhat positive on Monday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ViewRay earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.0210441026882 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- 13D Filing: OrbiMed Advisors and Viewray Inc (VRAY) – Insider Monkey (blog) (insidermonkey.com)
- Analysts Recommendations ViewRay, Inc. (VRAY) – Newsline (newsline.com)
- ViewRay Raises $50 Million through Sale of Common Stock (finance.yahoo.com)
- An Eye on Data – ViewRay, Inc., (NASDAQ: VRAY) – Stock Watch (stocksnewstimes.com)
Shares of ViewRay (NASDAQ VRAY) traded down 3.87% during mid-day trading on Monday, hitting $6.70. 608,302 shares of the stock were exchanged. ViewRay has a 1-year low of $2.67 and a 1-year high of $10.39. The firm’s market cap is $395.35 million. The company’s 50-day moving average is $6.13 and its 200-day moving average is $6.13.
ViewRay (NASDAQ:VRAY) last announced its earnings results on Monday, August 7th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.02). The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.68 million. During the same quarter in the previous year, the firm earned ($0.32) EPS. ViewRay’s revenue was up 133.3% compared to the same quarter last year. Equities research analysts anticipate that ViewRay will post ($0.82) earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. Mizuho reaffirmed a “buy” rating and issued a $12.00 price target on shares of ViewRay in a research note on Wednesday, October 25th. ValuEngine lowered shares of ViewRay from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Finally, Aegis reaffirmed a “buy” rating and issued a $11.00 price target on shares of ViewRay in a research note on Saturday, July 22nd. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $10.00.
WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/10/30/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-viewray-vray-share-price.html.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
What are top analysts saying about ViewRay Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ViewRay Inc. and related companies.